The FDA has accepted and granted Priority Review to an application for lower doses of leniolisib to treat younger children with activated phosphoinositide 3-kinase delta syndrome.

The intravenous immune globulin replacement therapy is currently being evaluated in a phase 3 clinical trial assessing motor function and mobility in adult patients with stiff person syndrome.

Routine FDA testing found patulin above safety limits in Wholesome Pantry jars sold at ShopRite and four other chains ...

Topline phase 3 findings show the KIT receptor inhibitor barzolvolimab significantly reduced itch and hives while achieving high complete response rates in patients with chronic spontaneous urticaria.

HealthDay News — Nutritional deficiencies are a common and underrecognized risk among pediatric patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment, according to a study ...

Approval is supported by phase 3 INShore trial data demonstrating 95% sustained complete remission at 52 weeks with obinutuzumab compared with 73% with MMF.

Probiotic supplement use has surged in the United States, while the consumption of microbiome-supportive foods has remained unchanged, according to a study publ ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.

The sNDA approval provides clinicians with the first FDA-cleared photodynamic therapy for skin cancer, backed by phase 3 trial data demonstrating superior clinical and histologic clearance.

The FDA approved Bravnetsa as the first radioligand therapy through the Abbreviated New Drug Application pathway, offering a bioequivalent alternative to Lutathera for adult patients with ...

Eleven-point-four percent of patients who underwent liver transplantation for cirrhosis developed cirrhosis subsequent to transplant.

HealthDay News — For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to ...